Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. HSIC
HSIC logo

HSIC Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
80.210
Open
80.100
VWAP
79.83
Vol
2.08M
Mkt Cap
9.10B
Low
79.375
Amount
166.38M
EV/EBITDA(TTM)
12.70
Total Shares
113.92M
EV
13.93B
EV/OCF(TTM)
24.10
P/S(TTM)
0.71
Henry Schein, Inc. is a solutions company for health care professionals. Its segments consist of Global Distribution and Value-Added Services, Global Specialty Products and Global Technology. Global Distribution and Value-Added Services include distribution to the global dental and medical markets of national brand and corporate brand merchandise, as well as equipment and related technical services. This segment also includes value-added services such as financial services, continuing education services, consulting and other practice services. This segment also markets and sells, under its own corporate brand, a portfolio of consumable merchandise. Global Specialty Products includes manufacturing, marketing and sales of dental implant and biomaterial products; endodontic, orthodontic and orthopedic products and other health care-related products and services. Global Technology includes development and distribution of practice management software, e-services, and other products.
Show More

Events Timeline

(ET)
2026-05-22
08:10:00
Henry Schein Appoints Daniel as Independent Chairman of the Board
select
2026-05-05 (ET)
2026-05-05
06:10:00
Reaffirms FY26 Sales Growth View at 3%-5%
select
2026-05-05
06:10:00
Henry Schein Q1 Revenue of $3.4B Beats Expectations
select

News

CNBC
6.0
06-11CNBC
Latest Wall Street Ratings Overview
  • SpaceX Initiation: New Street initiates SpaceX with a buy rating, projecting a 75% market share in a $2.3 trillion market, suggesting a fair value of $330 per share if the company captures 50% of the high-end market estimate, indicating strong potential in the space industry.
  • Intel Double Upgrade: Bank of America upgrades Intel from underperform to buy, citing increased confidence in its opportunities in leading-edge wafers and packaging, which is expected to enhance its share in the larger CPU market, reflecting a positive outlook for the semiconductor sector.
  • AMD Price Target Increase: Bank of America raises AMD's price target from $500 to $560, highlighting its leading position in the CPU market and the upcoming AI Day (Venice launch), indicating strong performance driven by technological innovation and market demand.
  • Netflix Outperformance: Evercore ISI reiterates Netflix as outperform, with surveys showing robust core metrics in both U.S. and UK markets, particularly in the adoption of ad-supported subscription offerings, demonstrating its solid position in the competitive streaming market.
Newsfilter
5.0
05-22Newsfilter
Henry Schein Appoints New Board Chairman
  • New Board Chairman: Henry Schein announced that William K. 'Dan' Daniel will become the Independent Chairman of the Board effective May 21, 2026, succeeding Stanley M. Bergman, who served 44 years and is now Chairman Emeritus, recognizing his extraordinary contributions to the company.
  • Rich Leadership Experience: Daniel joined the Henry Schein Board in May 2025 and brings decades of board and global executive leadership experience in healthcare and industrial sectors, having served 14 years as Executive Vice President at Danaher Corporation, overseeing multiple business segments including the dental portfolio.
  • Strategic Continuity and Growth: Daniel expressed his commitment to building upon the foundation laid by Bergman, emphasizing the latter's strategic leadership and dedication to Henry Schein's mission, which has shaped the company into a leading industry provider, and he looks forward to supporting this legacy.
  • Growth Outlook: CEO Fred Lowery expressed gratitude for Bergman's contributions and highlighted that Daniel's deep understanding of the business and distinguished track record will be instrumental in executing the company's long-term strategy, enhancing the quality and accessibility of healthcare services.
Newsfilter
6.5
05-14Newsfilter
2026 Catalyst Index Released, Clinical Execution Drives Growth
  • Industry Performance Analysis: The 2026 Catalyst Index reveals that top performers achieve a 75% case acceptance rate, significantly higher than the industry average of 45%, indicating that clinical consistency drives predictable growth and enterprise value more than scale alone.
  • Importance of Clinical Execution: The report emphasizes that growth is no longer solely reliant on scale or efficiency but is driven by clinical execution, with top organizations outperforming peers by delivering more complete and consistent care, which directly impacts financial outcomes.
  • Decline in Patient Retention: Despite improvements in operational metrics like scheduling efficiency, patient retention has dropped from 72% to 64%, signaling that efficiency gains are not translating into long-term growth, highlighting the need for a focus on patient communication and case acceptance.
  • Market Strategy Insights: For operators and investors, the report clearly states that growth strategies based solely on scale increase complexity, while expanding through consistent clinical execution drives predictable performance and long-term value creation.
Newsfilter
7.5
05-12Newsfilter
Activist Investor Sees Doubling Potential for BWX Technologies
  • Significant Market Potential: Ananym Capital Management believes BWX Technologies' stock could double in the coming years, primarily driven by the commercialization of its mothballed nuclear reactor design to meet surging energy demand.
  • Stock Price Growth Drivers: With a market value of $19 billion, BWX Technologies' shares have risen approximately 93% over the past 12 months, fueled by increasing energy needs, defense spending, and investments in nuclear power.
  • Diverse Value Creation Paths: Ananym argues that BWX Technologies could see its stock price grow by about 45% as a supplier to large reactor and small modular reactor manufacturers, and with no clear market leader, BWX has the opportunity to develop its mPower technology independently or through joint ventures.
  • Policy Support Outlook: The Trump administration has set a goal to quadruple nuclear energy capacity by 2050, providing policy backing for BWX Technologies' future growth and enhancing its competitive position in the market.
Newsfilter
9.5
05-05Newsfilter
Henry Schein Exceeds Q1 Profit Expectations, Reaffirms Annual Forecast
  • Strong Earnings Beat: Henry Schein reported adjusted earnings of $1.32 per share for Q1, up 14.8% from $1.15 a year earlier and exceeding analysts' expectations of $1.22, indicating robust profitability.
  • Revenue Growth: The company achieved a 6.3% increase in total revenue to $3.4 billion, surpassing the average analyst estimate of $3.34 billion, reflecting strong demand in the medical supply market.
  • Segment Performance: The Global Distribution and Value-Added Services segment saw a revenue increase of 6.1% to $2.84 billion, while the Global Specialty Products segment rose 8.1% to $397 million, showcasing solid growth across multiple business areas.
  • Optimistic Outlook: Henry Schein reaffirmed its 2026 adjusted profit forecast of $5.23 to $5.37 per share and expects annual sales growth of about 3% to 5%, demonstrating confidence in future market stability.
seekingalpha
9.5
05-05seekingalpha
Henry Schein Q1 Earnings Exceed Expectations
  • Strong Earnings Performance: Henry Schein reported a Q1 non-GAAP EPS of $1.32, beating expectations by $0.10, indicating sustained profitability and bolstering investor confidence in the company's financial health.
  • Significant Revenue Growth: The total revenue for Q1 reached $3.37 billion, marking a 6.3% year-over-year increase and exceeding expectations by $30 million, reflecting the company's strong market performance and effective sales strategies.
  • Diverse Sources of Sales Growth: The quarter's sales growth was driven by 2.5% internal sales growth, 0.7% from acquisitions, and a 3.1% increase due to foreign currency exchange, showcasing the company's success in diversifying its revenue streams.
  • Stable 2026 Outlook: Henry Schein maintains its 2026 non-GAAP diluted EPS guidance at $5.23 to $5.37, aligning with consensus, while total sales growth is expected to remain between 3% and 5%, reflecting confidence in future performance.
Wall Street analysts forecast HSIC stock price to rise
10 Analyst Rating
Wall Street analysts forecast HSIC stock price to rise
5 Buy
3 Hold
2 Sell
Moderate Buy
Current: 0.000
sliders
Low
58.00
Averages
76.78
High
90.00
Current: 0.000
sliders
Low
58.00
Averages
76.78
High
90.00
BTIG
upgrade
AI Analysis
2026-06-11
Reason
BTIG
Price Target
AI Analysis
2026-06-11
upgrade
Reason
BTIG upgraded Henry…
UBS
Kevin Caliendo
Neutral
downgrade
$87 -> $85
2026-05-06
Reason
UBS
Kevin Caliendo
Price Target
$87 -> $85
2026-05-06
downgrade
Neutral
Reason
UBS analyst Kevin Caliendo lowered the firm's price target on Henry Schein to $85 from $87 and keeps a Neutral rating on the shares.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for HSIC
Unlock Now

Valuation Metrics

The current forward P/E ratio for Henry Schein Inc (HSIC.O) is 14.95, compared to its 5-year average forward P/E of 15.31. For a more detailed relative valuation and DCF analysis to assess Henry Schein Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
15.31
Current PE
14.95
Overvalued PE
16.97
Undervalued PE
13.64

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
11.78
Current EV/EBITDA
11.03
Overvalued EV/EBITDA
12.53
Undervalued EV/EBITDA
11.03

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
0.75
Current PS
0.64
Overvalued PS
0.85
Undervalued PS
0.64

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

stock fot today buy and sell
Intellectia · 1185 candidates
Market Cap: >= 5.00BRegion: USRelative Vol: >= 2List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20, PriceBelowMA20Week Price Change Pct: $-12.00 - $12.00Monthly Average Dollar Volume: >= 1,500,000
Ticker
Name
Market Cap$
top bottom
PAAS logo
PAAS
Pan American Silver Corp
27.50B
VIAV logo
VIAV
Viavi Solutions Inc
6.33B
XP logo
XP
XP Inc
11.25B
HSIC logo
HSIC
Henry Schein Inc
9.49B
WULF logo
WULF
Terawulf Inc
6.56B
SSL logo
SSL
Sasol Ltd
5.59B

Whales Holding HSIC

L
Lyrical Asset Management LP
Holding
HSIC
+20.33%
3M Return
K
KKR & Co. Inc.
Holding
HSIC
+20.27%
3M Return
S
Southpoint Capital Advisors LP
Holding
HSIC
+18.37%
3M Return
G
Greenlight Capital, Inc.
Holding
HSIC
+12.03%
3M Return
L
Leith Wheeler Investment Counsel Ltd.
Holding
HSIC
+11.21%
3M Return
S
Snyder Capital Management, L.P.
Holding
HSIC
+9.78%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Henry Schein Inc (HSIC) stock price today?

The current price of HSIC is 79.92 USD — it has decreased -0.06

What is Henry Schein Inc (HSIC)'s business?

Henry Schein, Inc. is a solutions company for health care professionals. Its segments consist of Global Distribution and Value-Added Services, Global Specialty Products and Global Technology. Global Distribution and Value-Added Services include distribution to the global dental and medical markets of national brand and corporate brand merchandise, as well as equipment and related technical services. This segment also includes value-added services such as financial services, continuing education services, consulting and other practice services. This segment also markets and sells, under its own corporate brand, a portfolio of consumable merchandise. Global Specialty Products includes manufacturing, marketing and sales of dental implant and biomaterial products; endodontic, orthodontic and orthopedic products and other health care-related products and services. Global Technology includes development and distribution of practice management software, e-services, and other products.

What is the price predicton of HSIC Stock?

Wall Street analysts forecast HSIC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HSIC is76.78 USD with a low forecast of 58.00 USD and a high forecast of 90.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Henry Schein Inc (HSIC)'s revenue for the last quarter?

Henry Schein Inc revenue for the last quarter amounts to 3.37B USD, increased 6.31

What is Henry Schein Inc (HSIC)'s earnings per share (EPS) for the last quarter?

Henry Schein Inc. EPS for the last quarter amounts to 0.92 USD, increased 4.55

How many employees does Henry Schein Inc (HSIC). have?

Henry Schein Inc (HSIC) has 25000 emplpoyees as of June 21 2026.

What is Henry Schein Inc (HSIC) market cap?

Today HSIC has the market capitalization of 9.10B USD.